PharmaEngine
Taiwanese pharmaceutical company focused on cancer drug development, with ONIVYDE® and pipeline projects PEP07 and PEP08.
Last updated September 10, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
PharmaEngine is a Taiwanese pharmaceutical company that began operations in February 2003, adopting a "Virtual Pharmaceutical Company Business Model" focused on new drug development through international strategic alliances. It focuses on cancer treatment. Its product ONIVYDE® is a liposomal formulation of a camptothecin-class anticancer drug developed using nanotechnology, used in the treatment of metastatic pancreatic cancer patients, and has been launched in the United States, Europe, and multiple major Asian countries. Its pipeline includes PEP07, a cell damage regulatory enzyme inhibitor in Phase I clinical trials, and PEP08, a PRMT5 inhibitor in Phase I clinical trials. The company is headquartered in Taipei, Taiwan.
History
PharmaEngine began operations in February 2003. The company was founded on the concept of international strategic alliances, using a "Virtual Pharmaceutical Company Business Model" focused on new drug development to reduce the risks of drug development. Leveraging its extensive experience in project management, PharmaEngine introduced and led multiple new drug projects, conducting (pre-)clinical research and subsequent commercialization development. In March 2023, the company was certified by the Ministry of Economic Affairs as a "Biotechnology and Pharmaceutical Company."
Products and positioning
ONIVYDE®
A liposomal formulation of a camptothecin-class anticancer drug developed using nanotechnology. It is a type I DNA topoisomerase I inhibitor that blocks the enzyme to inhibit cancer cell growth. Used in the treatment of metastatic pancreatic cancer patients, it has been launched in the United States, Europe, and multiple major Asian countries.
PEP07
A cell damage regulatory enzyme inhibitor (CHK1 inhibitor), currently in Phase I clinical trials.
PEP08
A PRMT5 inhibitor, currently in Phase I clinical trials.
LIPORAXEL®
Oral paclitaxel solution introduced for sale in Taiwan in November 2024.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/智擎生技 · Editorial policy · How profiles are compiled